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Abstract
Previous studies of associations between ASD and conception using assisted reproductive 
technology (ART) are inconsistent and few studies have examined associations with other 
infertility treatments or infertility disorders. We examined associations between ASD and 
maternal/paternal infertility disorders and numerous maternal treatments among 1538 mother–
child pairs in the Study to Explore Early Development, a population-based case-control study. 
ASD was associated with any female infertility diagnosis and several specific diagnoses: blocked 
tubes, endometriosis, uterine-factor infertility, and polycystic ovarian syndrome. Stratified 
analyses suggested associations were limited to/much stronger among second or later births. The 
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findings were not explained by sociodemographic factors such as maternal age or education or 
multiple or pre-term birth. ASD was not associated with ART or non-ART infertility treatments.
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Autism spectrum disorder; Neurodevelopmental disorders; Infertility; Reproductive techniques; 
assisted; Ovulation induction; Epidemiology
Introduction
The U.S. prevalence of autism spectrum disorder (ASD) in children is estimated at 1–2% 
(Christensen et al. 2016; Blumberg et al. 2013). While much remains unknown about the 
etiology of ASD, epidemiologic studies suggest that in addition to genetics, ASD is 
associated with maternal health conditions prior to pregnancy, such as diabetes and 
autoimmune disorders, and maternal complications and exposures during pregnancy (Ornoy 
et al. 2016; Schieve et al. 2011). Further, neurobiological and clinical research indicates that 
children with ASD have very early alterations in brain development (i.e. during fetal 
development) (Young et al. 2016; Arndt et al. 2005; Bauman and Kemper 2005) and that 
developmental delays are evident as early as infancy in many children eventually diagnosed 
with ASD (Bolton et al. 2012). Given the importance of the preconception and prenatal 
periods in the etiology of ASD, and research suggestive of a link between ASD and in utero 
hormonal exposure (Wen and Wen 2014), maternal infertility disorders and treatments are of 
interest as potential ASD risk factors.
Several previous studies have assessed associations between conception with the assistance 
of infertility treatments and ASD. Most have assessed only the relationship between ASD 
and assisted reproductive technologies (ARTs) because such data are available from ART 
registries (Fountain et al. 2015; Sandin et al. 2013; Zachor and Ben Itchach 2011; Knoester 
et al. 2007; Klemetti et al. 2006). Study findings have been inconsistent. Moreover, in 
several studies that initially documented associations between conception using ART and 
ASD in offspring, further investigation revealed that a large component of the association 
was explained by earlier identification of ASD in children conceived with ARTs (Schieve et 
al. 2015) and/or the known associations of both ASD and ART with multiple birth and 
preterm birth among singletons (Fountain et al. 2015; Sandin et al. 2013; Hvidtjorn et al. 
2011; Klemetti et al. 2006). Two studies suggested that while ART had little or no 
association with ASD overall, one specific and particularly intensive ART treatment—
intracytoplasmic sperm injection (ICSI)—was possibly associated with ASD and/or 
intellectual disability (Kissin et al. 2015; Sandin et al. 2013). The few studies that examined 
a range of both ART and non-ART treatments reported mixed results. One reported no 
associations between ASD and any of the treatments examined (Lyall et al. 2013). In 
contrast, two studies found no associations with ART, but significant positive associations 
between ASD and less invasive treatments—non-ART ovulation induction and/or assisted 
insemination (Hvidtjorn et al. 2011; Lyall et al. 2012). A possible reason for these seemingly 
anomalous results is that infertility treatments might not be direct risk factors, but rather 
indicate associations with underlying maternal or paternal infertility disorders that lead to 
Schieve et al. Page 2
J Autism Dev Disord. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the need for an infertility treatment. However, neither study had sufficiently detailed data to 
examine the underlying mechanisms for the associations observed.
Only a few studies have directly examined the relationship between ASD and infertility 
disorders (Grether et al. 2013; Lyall et al. 2012, 2013). While one study initially documented 
associations between ASD and several infertility indicators, the associations were attenuated 
and no longer reached statistical significance when limited to singleton births (Grether et al. 
2013). However, given that a few risk ratios remained elevated, a possible modest 
association cannot be ruled out. Two other case-control studies observed no association 
between ASD and infertility. One was limited by small sample sizes which precluded 
detailed analyses of specific types of infertility (Lyall et al. 2013). The other had a larger 
sample size, but had potential methodological shortcomings, particularly in ascertainment of 
infertility in mothers; further, the findings from this study might have limited 
generalizability, given the study population was a very select group of predominantly white 
nurses and their children (Lyall et al. 2012). Other recent studies suggest a positive 
association with ASD and one specific infertility diagnosis—maternal polycystic ovarian 
syndrome (PCOS) (Kosidou et al. 2016; Palomba et al. 2012).
Gaps remain in our understanding of whether either infertility disorders or their treatments 
are associated with ASD. There is a particular need for additional studies of infertility 
disorders and non-ART treatment. The Study to Explore Early Development (SEED), a 
multi-site case-control study of ASD risk factors, provided an opportunity for in depth 
assessments of both infertility disorders and a large range of treatments used by women to 
assist with both conception and early pregnancy maintenance. SEED offers several 
advantages to other studies. SEED included detailed data collection of potential ASD risk 
factors, as well as a rigorous case ascertainment methodology. Cases were identified from 
multiple educational and clinical sources serving diverse population groups. Case 
classification was based on in depth standardized in-person developmental assessments 
administered by research-reliable clinical study staff, rather than on reports of past clinical 
diagnoses. Exposure ascertainment was based on detailed maternal reproductive histories 
taken as part of a comprehensive maternal telephone interview administered by interviewers 
who were extensively trained. Finally, SEED's sample size allowed for more detailed 
subgroup analyses than several other previous studies.
Methods
SEED Methodology
SEED, a multi-site case-control study funded by the Centers for Disease Control and 
Prevention (CDC), was implemented in 2007 in six sites located in CA, CO, GA, MD, NC, 
and PA. Institutional Review Boards at CDC, each study site, and the SEED Data 
Coordinating Center at Michigan State University approved the SEED protocol. Study 
methods have been described in detail previously (Schendel et al. 2012) and are summarized 
here.
Each site enrolled three groups of children—children with ASD (ASD group), children with 
other non-ASD developmental disabilities (DD group), and children from the general 
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population (POP group). Children for the ASD and DD groups were identified from multiple 
special education and clinical sources that provide services to children with disabilities. 
Children recruited from each source were those with select special education or International 
Classification for Disease codes indicative of autism/ASD or other DDs often seen as 
precursor or co-occurring diagnoses in children eventually diagnosed with ASD. The POP 
group is composed of a random sample of children selected from birth certificates within a 
given site's defined geographic study area.
Recruitment, enrollment, and data collection activities for the first phase of SEED occurred 
from 2007 to 2012. Eligible children were born between 2003 and 2006, lived in the 
respective site's study area both at birth and at study enrollment, and lived with a caregiver 
since 6 months of age who could provide legal consent and was capable of communicating 
in English (all sites) or Spanish (two sites). Children were enrolled when they were 2–5 
years of age. Across sites, 22% of the potential ASD or DD families who were contacted 
were found to be ineligible, 34% refused participation before eligibility could be 
determined, and 43% were eligible and enrolled. Among potential POP families contacted, 
34% were known to be ineligible, 40% refused before eligibility could be determined, and 
25% were eligible and enrolled.
Although children were initially identified as potentially being eligible for a given study 
group—ASD, DD, or POP— the final study group classification was determined from 
standardized research developmental assessments. Upon enrollment, all children were 
screened for possible autism characteristics through their caregiver's completion of the 
Social Communication Questionnaire (SCQ). Children with SCQ scores above a 
predetermined threshold (≥11) were designated as potential ASD cases regardless of how 
they were initially identified. Additionally, all children who had a previous ASD diagnosis 
or autism special education classification were designated as potential ASD cases regardless 
of their SCQ scores. Children in all study groups were seen in person as part of the study 
protocol and administered a developmental assessment. Children in the potential ASD group 
underwent a more comprehensive assessment than children in the other groups. In addition 
to a general developmental assessment, they were administered the Autism Diagnostic 
Observation Schedule (ADOS) and their caregivers were administered the Autism 
Diagnostic Interview revised (ADI-R). Final ASD case classification was based on the 
ADOS and ADI-R scores.
A wealth of data was collected from children in all study groups and their caregivers, 
including an extensive interview with the caregiver about family socio-demographics and, if 
the caregiver was the biological mother (98% of respondents), her reproductive history and 
information about her pregnancy with the index child.
Sample Selection
This analysis was focused on a comparison of children with a final classification of ASD 
versus POP (n = 1930). The DD group included a heterogeneous mix of children with 
different types of developmental delays and disabilities ranging from genetic syndromes to 
diagnoses of general developmental delays only. Because we did not have sufficient sample 
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size to sub-divide the DD group into more meaningful analytic subgroups, we excluded 
them from the current analysis.
We excluded mother–child pairs missing data on infertility disorders and treatments (n = 
273) or confounders (n = 13). We additionally excluded 106 mother–child pairs with 
maternal age <20 years and/or maternal education <12 years because within these 
demographic subgroups, both the ASD and POP study participants had very low occurrence 
(n = 0–5) of both infertility disorders and infertility treatments (thus, they were non-
informative to this analysis). Our final sample included 1538 mother–child pairs: 629 ASD 
and 909 POP.
Infertility Exposures of Interest
We assessed two groups of exposures: (1) diagnosed infertility disorders; and (2) maternal 
treatments for infertility and/or to maintain pregnancy.
Infertility Disorders—The telephone interview with the child's mother included questions 
on whether before the index pregnancy a doctor or other healthcare provider ever told her it 
would be impossible or difficult to get pregnant—overall and because of specific infertility-
related disorders, including blocked or damaged fallopian tubes; PCOS or multiple ovarian 
cysts; diminished ovarian reserve because of advanced age, premature ovarian failure or a 
medical condition; endometriosis; uterine problem, such as fibroids; or a diagnosis of 
unexplained infertility. Women could respond affirmatively to more than one disorder. 
Women were also given the option of describing verbatim an “other” reason they were told it 
was difficult to get pregnant. We systematically examined all “other” responses and, when 
possible, classified them into one or more of the aforementioned infertility-related disorder 
categories. We were conservative in our approach by distinguishing definite and possible 
diagnoses. That is, in some instances, we classified a woman's response as possibly, but not 
definitely being related to a certain type of infertility disorder, most notably possible PCOS 
or possible uterine problem. For these two disorders, we constructed two analytic 
“exposure” variables, one with a strict interpretation of “other” responses and one with a 
more liberal interpretation that included the possible classifications. We did not have 
sufficient sample size to separately examine mutually-exclusive reports of every infertility 
disorder and infertility disorder combination reported. However, we did examine more than 
one maternal infertility disorder as a separate exposure category.
Women were also asked a single question about male factor infertility—whether the child's 
biological father had ever been told prior to the index pregnancy that it would be difficult for 
him to father a child because of problems with his sperm.
Maternal Infertility Treatments—All maternal respondents, regardless of their responses 
to the infertility disorders questions, were asked whether they used any type of treatment or 
medication to help them get pregnant with the index pregnancy and/or maintain the 
pregnancy in the early stages. If they responded affirmatively, they were specifically asked 
about medications used, including a lengthy pre-specified list of medications and an option 
to provide the name of their medication(s) verbatim; assisted reproductive technology 
treatments (ARTs); assisted or artificial insemination; and surgery for an infertility condition 
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within the 6 months preceding the index pregnancy. Women could respond affirmatively to 
more than one treatment. We systematically examined all medication, procedure, and 
surgery verbatim responses. In a few instances, we determined that a response did not meet 
criteria for an infertility treatment—examples included folic acid and Rhogam medications. 
However, most “other” responses corresponded with a valid type of infertility treatment.
We classified all medications reported into the following subtypes: ovarian stimulation-anti-
estrogen; ovarian stimulation-gonadotropin; progesterone; human chorionic gonadotropin 
(hCG) and related; gonadotropin agonist/antagonist; other hormonal medication, such as 
estrogen; and other medication to prevent miscarriage, including anti-inflammatory 
medications and anticoagulants. Since many women used multiple treatments, we also 
created a mutually-exclusive hierarchy of treatments. Results were comparable when we 
considered each factor individually versus in a mutually-exclusive hierarchy; we therefore 
present only the former here.
Potential Confounders
We examined several demographic factors previously found to be associated with ASD 
diagnosis and ART use as potential confounders or effect modifiers. These included 
maternal race-ethnicity; maternal age, education and parity at index birth; and child sex. 
Because previous studies suggest preterm birth and/or multiple birth might be factors in the 
causal pathway between infertility treatments and ASD (Fountain et al. 2015; Sandin et al. 
2013; Hvidtjorn et al. 2011; Klemetti et al. 2006), we also examined all analyses in sub-
samples restricted to term births (≥37 weeks' gestation) and singleton births.
Child sex and maternal age were ascertained as part of the enrollment intake process. 
Maternal education, race-ethnicity, parity, and plurality were collected in the maternal 
telephone interview. Gestational age was provided in birth certificate files provided by each 
site for enrolled participants.
Statistical Analysis
In initial analyses, we examined percent distributions of all infertility disorders, infertility 
treatments and potential confounders by study group. We assessed statistical significance of 
differences with Chi square tests. We calculated crude and adjusted odds ratios (ORs, aORs) 
and corresponding 95% confidence intervals (CIs) for associations between ASD and each 
infertility disorder and each infertility treatment variable. Adjusted ORs were estimated from 
logistic regression models that included maternal age, education, and parity at index birth, 
maternal race-ethnicity, and child sex in addition to the infertility disorder/treatment of 
interest. We conducted stratified analyses to assess whether ORs varied substantially by any 
of the aforementioned potential confounders. We noted marked, consistent variation in aORs 
for several infertility disorder associations across parity strata. We therefore also present 
separate adjusted analyses of infertility disorders for children who were first births and 
second or later births.
To better understand the effect differences observed between infertility disorders and parity, 
we re-ran analyses of infertility disorders within two additional sub-samples of second or 
later births: (1) restriction to mother–child pairs in which none of the index child's older 
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siblings had an ASD diagnoses; and (2) restriction to mother–child pairs in which the index 
pregnancy was not conceived after a short interval (<18 months) from the preceding birth. 
For this latter set of analyses, we separately examined subsets with an inter-pregnancy 
interval (IPI) of 18–59 months and an IPI of 60+ months. We did not combine these two 
groups because IPI of 60+ months has itself been found to be associated with ASD risk 
(Conde-Agudelo et al. 2016).
We also ran all of the models for associations with each infertility disorder and each 
infertility treatment in sub-samples restricted to term births and singleton births to assess 
whether preterm or multiple birth might be potential causal path factors.
Finally, we assessed the joint and separate effects of maternal infertility disorders and 
treatments in models that examined associations between ASD and (1) maternal infertility 
disorder (any type) but no maternal infertility treatment reported (any type); (2) maternal 
infertility treatment but no maternal infertility disorder reported; and (3) both maternal 
infertility disorder and treatment reported. We did not have sufficient sample size to assess 
individual disorders and treatments in this analysis series.
Results
Children with ASD were more likely than children in the POP sample to be male, a multiple 
birth, and born preterm (Table 1). Mothers of children with ASD were less likely than 
mothers of POP children to be NHW and have an advanced education at the time of their 
child's birth; they were also younger.
Infertility Disorders
In both unadjusted and adjusted analyses, we observed significant positive associations 
between ASD and diagnosis of maternal infertility generally, and diagnoses of blocked/
damaged fallopian tubes, endometriosis, and uterine problems specifically; ORs and aORs 
ranged from 1.4 to 2.6 (Table 2). Stratified analyses indicated that these associations were 
limited to or much stronger in second or later births (aORs ranged from 1.9 to 6.3). 
Additionally, stratification revealed a significant association between ASD and PCOS and a 
nearly significant association between ASD and more than one maternal infertility disorder 
among second or later births (aORs ranged from 2.0 to 2.7). ASD was not associated with 
maternal diminished ovarian reserve or unexplained infertility. However, the effect estimates 
for unexplained infertility were imprecise due to low prevalence. ASD was also not 
associated with male-factor infertility.
The findings in Table 2 were similar in samples restricted to singletons and term births 
(Supplemental Table 1). In supplemental analyses of second or later births, we observed a 
similar pattern of results after excluding children from the sample who had an older sibling 
with an ASD diagnosis (a general indication of a possible genetic link to ASD) 
(Supplemental Table 2). We also observed a fairly similar pattern of results in subsets of 
second or later births conceived 18–59 months or 60+ months after the previous birth 
(Supplemental Table 2). However, all estimates were imprecise as evidenced by wide 
confidence intervals. While point estimates generally followed a similar pattern as that 
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observed for the total sample of second or later births, a few associations appeared 
attenuated and others appeared strengthened. However, given the imprecision of estimates, 
those few departures from the general pattern might not be meaningful and thus, should be 
interpreted cautiously.
Treatment for Infertility or to Maintain Pregnancy
Although none of the findings were statistically significant, mothers of children with ASD 
were slightly more likely to have used an infertility treatment than mothers of POP children 
(Table 3). They had 20% higher odds of use of any maternal infertility treatment, and 20–
50% higher odds of use of six of the nine specific infertility-related medications or 
procedures we examined: gonadotropin ovarian stimulation medications, progesterone 
medications, hCG medications; gonadotropin agonist/antagonist medications, other 
medications to prevent miscarriage, and ART. These findings are difficult to interpret, given 
case-control differences are modest and sample sizes for most treatments were low (<4% use 
in POP group for 5 of the 6 aforementioned treatments) and thus confidence intervals all 
included 1.0 both before and after adjustment. However, we note that the direction and 
magnitude of difference between cases and controls was consistent across treatments. 
Moreover, for all of the aforementioned treatments, aORs were attenuated in the sample 
restricted to singletons, and most were also attenuated in the sample restricted to term births.
Separate and Joint Effects Maternal Infertility Disorders and Treatments
Among 185 case mothers and 217 control mothers who reported either an infertility disorder 
or treatment, roughly one-third reported an infertility disorder only, one-third reported an 
infertility treatment only, and one-third reported both a disorder and a treatment. As 
observed for all infertility disorders together (Table 2), ASD was associated with both 
maternal infertility disorder with treatment and maternal infertility disorder without 
treatment in second or later births but not first births (Table 4). ASD was not associated with 
infertility treatment if a diagnosed infertility disorder had not been reported. Although 
sample size was too small for detailed analyses of individual disorders or treatments, we 
examined the types of infertility disorders reported by case and control mothers with and 
without treatment and the types of infertility/early pregnancy maintenance treatments 
reported by case and control mothers with and without a disorder (Supplemental Table 3). 
While some variability was observed, it was noteworthy that the full range of disorders was 
reported by case and control mothers regardless of whether they used a treatment for the 
index pregnancy. Likewise, the full range of treatments was reported for case and control 
mothers whether or not they reported a past infertility disorder diagnosis.
Discussion
Infertility Disorders
We document several positive associations between ASD and maternal infertility, including 
several specific diagnoses of infertility disorders. These associations varied by birth order 
(parity). While the magnitude of the aORs among second or later births was near or above 
3.0 for four conditions (blocked tubes, PCOS, endometriosis, and uterine or related 
problems), indicating strong associations with ASD, aORs were markedly lower among first 
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births. For two conditions (blocked tubes and PCOS), the findings were null among first 
births and for the other two conditions (endometriosis and uterine and related problems) 
aORs (1.8 and 1.6, respectively) were 45–71% lower among first births and the confidence 
intervals for these estimates overlapped 1.0.
These finding of differential effects by birth order were unexpected. Since multiparous 
women are more likely to be of advanced maternal age, we considered whether these 
findings reflected a maternal-age effect. However, our findings persisted after adjustment for 
maternal age as well as after adjustment for maternal education and race-ethnicity and child 
sex. Additionally, we ruled out multiple birth, preterm birth, short IPI, and possible genetic 
effects as underlying explanations for the parity differences. However, the estimates from 
our analyses restricted to children conceived at least 18 months after a previous birth were 
imprecise and thus, while the general pattern of results suggests infertility disorders remain a 
risk factor for ASD after removing the effect of short IPI, our sample was under-powered to 
examine this issue for many individual conditions. Additionally, we could not fully evaluate 
other potential explanations. For example, some studies indicate that endometriosis and 
uterine fibroids are associated with various pregnancy complications, including strong 
associations with placenta previa (Berlac et al. 2017; Parazzini et al. 2016) Placenta previa 
has been shown to occur more frequently in multiparous births (Ananth et al. 1996). We 
lacked data to examine this hypothesis. We also lacked data to examine whether infertility 
conditions were more severe or had been diagnosed later in women on their second or later 
birth than first birth.
Despite the remaining questions related to the effect modification by birth order, the 
consistency of our findings of positive associations across several infertility conditions 
potentially supports their validity. Moreover, an association between infertility disorders and 
ASD has biological plausibility. All four disorders we found to be associated with ASD have 
been linked to inflammation and various autoimmune conditions (Vannuccini et al. 2016; 
Tobias et al. 2015; Kes-kin Kurt et al. 2014; Bungum et al. 2014; Kobayashi et al. 2014; Ott 
et al. 2014; Kachuei et al. 2012; Horne and Critchley 2007; Confino and Radwanska 1992). 
Inflammation and auto-immunity have been implicated in ASD etiology as well (Ornoy et 
al. 2016). Additionally, the defining feature of PCOS is a hormonal imbalance and research 
suggests a relationship between prenatal androgen levels and autistic traits (Wen and Wen 
2014).
Few previous studies have assessed associations between ASD and infertility conditions and 
none have conducted as in depth analyses, including detailed stratified analyses of specific 
infertility conditions, as the current study. A case-control study of children born 1995–1998 
who were included in a healthcare organization database reported that mothers of case 
children were significantly more likely than mothers of control children to have a history of 
infertility prior to conception, to have sought an evaluation in an infertility specialty clinic, 
and to have received an infertility diagnosis (Grether et al. 2013). These associations were 
attenuated and no longer statistically significant after restriction to singleton births, which 
might suggest that some of the effect was explained by infertility treatments (which pose a 
high risk for multiple birth); however, none of the infertility treatments assessed by the 
authors were associated with ASD. This study was limited in that data regarding specific 
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infertility conditions were not presented. A second case-control study of children residing in 
several regions in California reported similar proportions of maternal or paternal infertility 
diagnoses for children with ASD and typically-developing control children (Lyall et al. 
2013); however, specific infertility conditions could not be fully assessed because of very 
small numbers of both case and control mothers reporting individual infertility conditions. A 
third study, using a nested case-control design drawn from the Nurse's Health Study (NHS), 
which had a larger sample to assess individual conditions, also reported no association 
between infertility conditions and ASD (Lyall et al. 2012). There were notable differences 
between this study and the current study, particularly in the ascertainment of infertility. The 
NHS infertility question series was more restrictive than the SEED infertility question series 
in that women were only asked about specific infertility causes if they first responded 
affirmatively to a question on whether they had tried to become pregnant for more than a 
year without success. SEED did not place this type of sequential “rule-out” criterion on 
women, which might have had a notable impact on ascertainment. Not all women will wait 1 
year before seeking an infertility assessment, particularly those of advanced age and those 
diagnosed with an infertility disorder prior to trying to become pregnant (i.e. those who had 
previously sought a diagnostic work up at young ages in response to symptomatology). The 
SEED questions were also more specific than NHS in that they asked women to report 
infertility-related conditions diagnosed by a doctor or other healthcare provider, while NHS 
question verbiage simply asked the woman to report the reason (cause) she had difficulty 
becoming pregnant. Also, in contrast to NHS, the SEED questions included explanatory 
descriptions for some conditions as part of the question verbiage, the instrument was 
administered via phone by trained interviewers who were provided definitions for all 
conditions such that they could answer participant questions, and the instrument allowed for 
verbatim reporting of “other” conditions. These “other” responses were systematically 
reviewed and coded for this study. Finally, NHS includes a very select segment of the 
population—registered nurses from select states— who likely differ from the general US 
population on various health conditions and healthcare seeking behavior. In contrast to the 
studies reporting null findings, two previous studies that examined the association between 
ASD or ASD symptoms and a single condition—maternal PCOS— reported positive 
associations (Kosidou et al. 2015; Palomba et al. 2012).
Treatment for Infertility or to Maintain Pregnancy
Although we observed that a slightly higher proportion of mothers of children with ASD 
than mothers of POP children had used a treatment to help them become pregnant or 
maintain their pregnancy, these findings were attenuated after restricting the sample to 
singleton births. Most effect estimates were also attenuated after restriction to term births. 
While none of our findings reached statistical significance, the findings of a modest effect 
overall with attenuation after restriction to singletons was consistent across the majority of 
treatments we examined in this study. Moreover, both the magnitude and attenuation of 
effects that we observed are consistent with most other previous large studies of the 
relationship between ASD and ART (Fountain et al. 2015; Sandin et al. 2013; Hvidtjorn et 
al. 2011; Klemetti et al. 2006). Thus, our findings support previous studies suggesting that 
maternal infertility treatments such as ART may be linked to ASD by increasing risk of 
multiple birth, or preterm birth.
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Few studies have examined non-ART infertility treatments. One study reported no 
differences between ASD cases and typically developing controls in either ART use or use 
of various non-ART infertility treatments (Lyall et al. 2013). Two other studies reported 
positive associations between use of non-ART ovulation induction medications and ASD, 
findings that were particularly noteworthy in that neither observed associations with ART, a 
treatment that nearly always includes high doses of ovulation induction medications (Lyall et 
al. 2012; Hvidtjorn et al. 2011). Those potentially paradoxical findings might suggest that 
the ASD-ovulation induction associations reported in those studies are not causal, but rather 
are related to a woman's underlying infertility status. This hypothesis is possibly supported 
by subgroup analyses in one study (Lyall et al. 2012), which revealed that the ASD-
ovulation induction medications association was limited to women of advanced maternal 
age. The authors posit that ovulation induction might have stimulated the release of “sub-
optimal” oocytes more often in older rather than younger women. Nonetheless, no definitive 
conclusions about the underlying reason for the observed ASD-ovulation induction 
association can be drawn based on the data presented in either study and a direct relationship 
cannot be ruled out. Given the limited study of non-ART infertility treatments to date, 
further study is warranted.
Separate and Joint Effects Maternal Infertility Disorders and Treatments
Our findings of the combined infertility disorder-infertility treatment variables substantiate 
our findings from our separate analyses of disorders and treatments. Receipt of an infertility-
related treatment without a prior infertility diagnosis was not associated with ASD, while 
having a past diagnosis of an infertility disorder was associated with ASD whether or not the 
woman had received a treatment just prior to or early in the index pregnancy. We did not 
collect information on the specific reasons women used an infertility or early pregnancy 
maintenance treatment for the index pregnancy, but in practice there is a wide variation in 
how long women try to conceive a pregnancy naturally prior to seeking help in becoming 
pregnant, and some women may be started on a course of treatment without first undergoing 
a full diagnostic work-up. Additionally, various treatments are used to achieve pregnancy for 
social reasons (i.e. single mothers) in addition to infertility reasons.
Study Limitations
The findings presented here must be interpreted in the context of several limitations. Even 
though our sample size included more than 600 children with ASD and more than 900 
population controls, it was not sufficient to examine several important subgroups, including 
ASD case subtypes, which might be etiologically distinct; nor was it sufficient to examine 
meaningful subgroups of the heterogeneous DD group enrolled in SEED. Future analyses 
that incorporate data from subsequent phases of SEED will be valuable in continuing to 
explore the relationships described here in both ASD and DD subgroups. Additionally, the 
findings presented here for individual infertility disorders and treatments should be 
interpreted cautiously, given small numbers of exposed cases and controls in some analyses.
Maternal infertility disorders and treatments were reported 3–5 years postpartum and thus, it 
is important to consider whether recall bias may have influenced our findings. Recall bias is 
most likely for factors for which: (1) recall is difficult generally; and (2) the respondent 
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believes the factor might be a contributor to the condition of interest (Grimes and Schulz 
2002; Coughlin 1990). In SEED, respondents were asked to recall infertility disorders that 
had been diagnosed by a healthcare provider. Women who obtain diagnoses of specific 
infertility conditions are those who either had difficulty conceiving a pregnancy and sought a 
medical evaluation or sought help for symptoms for a condition such as uterine fibroids or 
endometriosis. Thus, infertility disorder diagnoses should be fairly salient events. While we 
did not have data to directly assess the validity of maternally-reported infertility conditions 
or treatments, the findings from previous studies are generally reassuring. Barradas and 
colleagues (2012) found that estimates of maternally-reported ART use from the population-
based Pregnancy Risk Assessment Monitoring System were similar to estimates derived 
from ART provider reports to the National ART Surveillance System. De Boer and 
colleagues (2005) reported excellent specificity for self-reported infertility among a Dutch 
cohort of women who previously underwent ART (range 89–96% for specific types of 
infertility). Sensitivities were also moderate to good (65–84%) for tubal-factor infertility, 
male-factor infertility, hormonal infertility, and endometriosis; however, the sensitivity for 
uterine factor infertility was lower (46%), indicating uterine-factor might not be as salient of 
a diagnosis, especially in women with multiple types of infertility. Nonetheless, even if some 
under-reporting of infertility diagnoses occurred, it is unlikely that it was related to case 
status. While we cannot definitively rule out that respondents believed their infertility 
condition was the cause of their child's autism, the infertility disorder questions were a small 
part of a lengthy maternal interview which included questions on many pregnancy behaviors 
and exposures which would likely have been more concerning to women; thus, the infertility 
questions should not have stood out.
In contrast to many other ASD studies, SEED sought to enroll a diverse population-based 
sample by identifying potentially eligible case children from multiple clinical and education 
sources serving children throughout each site's catchment area and identifying potential 
control children from birth certificate samples. One drawback to this approach is that 
numerous families targeted for potential recruitment could not be located or contacted. It is 
likely that many of these families were actually ineligible for inclusion since our a priori 
eligibility criteria required children to have current as well as birth residence in the study 
catchment area; four sites also required parents to be able to communicate well in English. 
Given the low response rate, selection bias should be considered. In a separate study 
(currently unpublished) we conducted a detailed analysis to assess whether non-response 
was likely to have resulted in selection bias by assessing various risk estimates using data 
from one site that had access to some data on all families initially invited. We found that 
associations between ASD and several perinatal factors, such as preterm birth, were 
comparable between the final sample of enrolled participants who completed the study and 
the full sample of invited participants (unpublished data). Moreover, that study assessed 
select associations of maternally-reported factors, including maternal report of an infertility 
disorder, after weighting the final sample to align demographically with the initial invited 
sample of participants; no notable differences were observed in the findings from the 
weighted and unweighted (original) analyses.
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Study Strengths
Despite potential limitations, the SEED sample had many strengths, including 
comprehensive case classification methodology using instruments considered gold-standards 
for ASD diagnoses and detailed exposure ascertainment that allowed us to conduct a much 
more comprehensive analysis than other studies to date. Additionally, SEED recruitment 
methods resulted in a diverse group of both case and control children. And SEED was 
intentionally designed to identify children with undiagnosed ASD, which is likely more 
common in underserved segments of the population. Finally, while our sample size was not 
sufficient to examine all subgroup analyses of interest, it was nonetheless one of the largest 
studies to date with detailed data on a range of infertility treatments and disorders and 
intensive standardized identification and classification of ASD.
Conclusion
Our findings suggest maternal infertility disorders are associated with ASD. In our sample, 
this effect was limited to second or later births, but mechanisms for this effect modification 
are not apparent and need to be explored further. While infertility treatments appeared to be 
modestly associated with ASD in initial analyses, no associations between ASD and 
infertility treatments were observed in analyses restricted to singleton births. Further study 
will be important to more fully characterize the associations reported here and to explore 
mediation mechanisms that may be in play, with the ultimate goal being to fully inform 
women who have been diagnosed with these disorders of the potential risks of these 
disorders and their treatment so as to minimize adverse child neurodevelopment outcomes.
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Table 1
Demographic, pregnancy, and birth characteristics of study population according to case-
control group, Study to Explore Early Development
ASD (N = 629) % POP (N = 909) % p value
Child sex <0.0001
 Male 82.5 53.8
 Female 17.5 46.2
Parity of index birth 0.1121
 First birth 48.3 44.2
 Second or later birth 51.7 55.8
Maternal race-ethnicity <0.0001
 Non-Hispanic white 59.0 73.9
 Non-white and/or Hispanic 41.0 26.1
Maternal age at birth (years) 0.0080
 20–34 70.3 68.9
 35+ 29.7 31.1
Maternal education at birth (years completed) <0.0001
 12 14.2 8.3
 13–15 30.5 23.8
 16+ 55.3 68.0
Birth plurality
 Singleton 91.7 96.3 0.0001
 Multiple 8.3 3.7
Gestational age <0.0001
 Term, 37+ weeks 83.6 90.8
 Preterm, <37 weeks 16.4 9.2
ASD autism spectrum disorder case group, POP population control group
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